Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Fate Therapeutics Inc (NASDAQ: FATE) was $1.35 for the day, up 4.65% from the previous closing price of $1.29. In other words, the price has increased by $4.65 from its previous closing price. On the day, 1.55 million shares were traded. FATE stock price reached its highest trading level at $1.505 during the session, while it also had its lowest trading level at $1.34.
Ratios:
Our analysis of FATE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.04 and its Current Ratio is at 8.04. In the meantime, Its Debt-to-Equity ratio is 0.31 whereas as Long-Term Debt/Eq ratio is at 0.29.
On October 27, 2025, Wedbush Upgraded its rating to Outperform which previously was Neutral but kept the price unchanged to $7.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 04 ’25 when TAHL CINDY sold 9,037 shares for $1.06 per share. The transaction valued at 9,573 led to the insider holds 397,670 shares of the business.
Valamehr Bahram sold 14,466 shares of FATE for $15,396 on Aug 04 ’25. The President and CEO now owns 334,898 shares after completing the transaction at $1.06 per share. On Aug 04 ’25, another insider, TAHL CINDY, who serves as the Officer of the company, bought 9,037 shares for $1.06 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FATE now has a Market Capitalization of 155695088 and an Enterprise Value of 14199091. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.38 while its Price-to-Book (P/B) ratio in mrq is 0.59. Its current Enterprise Value per Revenue stands at 1.676 whereas that against EBITDA is -0.088.
Stock Price History:
The Beta on a monthly basis for FATE is 2.43, which has changed by -0.51086956 over the last 52 weeks, in comparison to a change of 0.19736934 over the same period for the S&P500. Over the past 52 weeks, FATE has reached a high of $3.50, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is 10.70%, while the 200-Day Moving Average is calculated to be 15.49%.
Shares Statistics:
FATE traded an average of 2.08M shares per day over the past three months and 2319960 shares per day over the past ten days. A total of 114.66M shares are outstanding, with a floating share count of 109.59M. Insiders hold about 4.97% of the company’s shares, while institutions hold 70.54% stake in the company. Shares short for FATE as of 1760486400 were 7544331 with a Short Ratio of 3.62, compared to 1757894400 on 9877527. Therefore, it implies a Short% of Shares Outstanding of 7544331 and a Short% of Float of 7.46.
Earnings Estimates
Its stock is currently analyzed by 10.0 different market analysts. The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.14 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$0.96 and -$1.37 for the fiscal current year, implying an average EPS of -$1.14. EPS for the following year is -$1.15, with 10.0 analysts recommending between -$0.94 and -$1.46.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for FATE’s current fiscal year. The highest revenue estimate was $13.6M, while the lowest revenue estimate was $3.54M, resulting in an average revenue estimate of $7.21M. In the same quarter a year ago, actual revenue was $13.63M
